Abstract
Background The rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an urgent need for the prevention and containment of disease outbreaks in communities. Although the gold standard is polymerase chain reaction (PCR), antigen tests such as immunochromatographic assay (ICA) and chemiluminescent enzyme immunoassay (CLEIA) that can yield results within 30 minutes.
Methods We evaluated performance of ICA and CLEIA using 34 frozen PCR-positive specimens (17 saliva and 17 nasopharyngeal swab) and 307 PCR-negative samples.
Results ICA detected SARS-CoV-2 in only 14 (41%) samples, with positivity of 24% in saliva and 59% in NPS. Notably, ICA detected SARS-CoV-2 in 5 (83%) of 6 samples collected within 4 days after symptom onset. CLEIA detected SARS-CoV-2 in 31 (91%) samples, with positivity of 82% in saliva and 100% in NPS. CLEIA was negative in 3 samples with low viral load by PCR.
Conclusions These results suggest that use of ICA should be limited to earlier time after symptom onset and CLEIA is more sensitive and can be used in situations where quick results are required.
- SARS-CoV-2
- COVID-19
- Antigen test
- Chemiluminescent enzyme immunoassay
- Lumipulse
- Espline
Competing Interest Statement
Espline SARS-CoV-2 and Lumipulse SARS-CoV-2 Ag kit were supplied by Fujirebio.
Funding Statement
This study was supported by Health, Labour and Welfare Policy Research Grants 20HA2002.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Ethics Board (Hokkaido University Hospital Division of Clinical Research Administration Number: 020-0116).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are included in Supplements.
List of abbreviations
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- PCR
- polymerase chain reaction
- LAMP
- loop-medicated isothermal amplification
- ICA
- immunochromatographic assay
- CLEIA
- chemiluminescent enzyme immunoassay
- COVID-19
- coronavirus disease-19
- NPS
- nasopharyngeal swab samples
- NAAT
- nucleic acid amplification test
- NIID
- National Institute of Infectious Diseases
- CI
- confidential interval
- Tp
- time for detecting positive results
- IQR
- interquartile range
